Differences Between Anticoagulated Patients With Ischemic Stroke Versus Intracerebral Hemorrhage.

Abstract

Background Data on the relative contribution of clinical and neuroimaging risk factors to acute ischemic stroke (AIS) versus intracerebral hemorrhage (ICH) occurring on oral anticoagulant treatment are scarce. Methods and Results Cross-sectional study was done on consecutive oral anticoagulant-treated patients presenting with AIS, transient ischemic attack (TIA), or ICH from the prospective observational NOACISP (Novel-Oral-Anticoagulants-In-Stroke-Patients)-Acute registry. We compared clinical and neuroimaging characteristics (small vessel disease markers and atherosclerosis) in ICH versus AIS/TIA (reference) using logistic regression. Among 734 patients presenting with stroke on oral anticoagulant treatment (404 [55%] direct oral anticoagulants, 330 [45%] vitamin K antagonists), 605 patients (82%) had AIS/TIA and 129 (18%) had ICH. Prior AIS/TIA, coronary artery disease, dyslipidemia, and worse renal function were associated with AIS/TIA (adjusted odds ratio [aOR] [95% CI] 0.51 [0.32-0.82], 0.48 [0.26-0.86], 0.55 [0.34-0.89], and 0.82 [0.75-0.90] per 10 mL/min). Prior ICH, older age, higher admission blood pressure, and statin treatment were associated with ICH (aOR [95% CI] 6.33 [2.87-14.04], 1.37 [1.04-1.81] per 10 years, 1.19 [1.10-1.29] per 10 mm Hg, and 1.81 [1.09-3.03]). Cerebral microbleeds and moderate-to-severe white matter hyperintensities contributed more to ICH (aOR [95% CI] 2.77 [1.34-6.18], and 2.62 [1.28-5.63]). Aortic arch, common and internal carotid artery atherosclerosis, and internal carotid artery stenosis ≥50% contributed more to AIS/TIA (aOR [95% CI] 0.54 [0.31-0.90], 0.29 [0.05-0.97], 0.48 [0.30-0.76], and 0.32 [0.13-0.67]). Conclusions In patients presenting with stroke on oral anticoagulant, AIS/TIA was 5 times more common than ICH. A high atherosclerotic burden (indicated by cardiovascular comorbidities and extracranial atherosclerosis) and prior AIS/TIA contributed more to AIS/TIA, while small vessel disease markers and prior ICH were stronger determinants for ICH. Registration URL: https://www.clinicaltrials.gov; Unique identifier: NCT02353585.

• Authors: Fabian Schaub, Alexandros A Polymeris, Sabine Schaedelin, Lisa Hert, Louisa Meya, Sebastian Thilemann, Christopher Traenka, Benjamin Wagner, David Seiffge, Henrik Gensicke, Gian Marco De Marchis, Leo Bonati, Stefan T Engelter, Nils Peters, Philippe Lyrer
• Journal: Journal of the American Heart Association (J Am Heart Assoc) Vol. 11 Issue 1 Pg. e023345 (01 04 2022) ISSN: 2047-9980 [Electronic] England
• PMID: 34935409 (Publication Type: Journal Article, Observational Study, Research Support, Non-U.S. Gov't)

Chemical References

• Anticoagulants

Topics

• Anticoagulants (adverse effects)
• Atherosclerosis (drug therapy)
• Cerebral Hemorrhage (chemically induced, diagnostic imaging, epidemiology)
• Cross-Sectional Studies
• Humans
• Ischemic Attack, Transient (drug therapy, epidemiology, etiology)
• Ischemic Stroke
• Stroke (drug therapy, etiology, prevention & control)